SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India surges as its arm receives VAI classification for Telangana facility

01 Apr 2026 Evaluate

Granules India is currently trading at Rs. 634.20, up by 13.05 points or 2.10% from its previous closing of Rs. 621.15 on the BSE.

The scrip opened at Rs. 625.35 and has touched a high and low of Rs. 638.50 and Rs. 625.00 respectively. So far 30045 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.00 on 25-Mar-2026 and a 52 week low of Rs. 412.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 640.00 and Rs. 600.25 respectively. The current market cap of the company is Rs. 15701.65 crore.

The promoters holding in the company stood at 38.82%, while Institutions and Non-Institutions held 31.03% and 30.15% respectively.

Granules India’s wholly owned subsidiary -- Granules Life Sciences (GLS) has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI).

The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025. The inspection is now closed, and no regulatory action has been recommended. This development further strengthens Granules India’s finished dosage manufacturing capabilities by enabling multi-site manufacturing for the approved products.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

654.40 3.60 (0.55%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×